These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 20399169

  • 1. [The French clinician's guide to the Kidney disease: Improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD)].
    Jean G, Chazot C.
    Nephrol Ther; 2010 Jun; 6(3):151-7. PubMed ID: 20399169
    [Abstract] [Full Text] [Related]

  • 2. [The new Kidney Disease: Improving Global Outcomes (KDIGO) guideline for the mineral and bone disorder associated with chronic kidney disease (MBD-CKD)].
    Drüeke TB.
    Nephrol Ther; 2010 Jun; 6(3):149-50. PubMed ID: 20188646
    [No Abstract] [Full Text] [Related]

  • 3. KDIGO CKD-MBD Discussion forum: the Brazilian perspective.
    Moysés RM, Cancela AL, Gueiros JE, Barreto FC, Neves CL, Canziani ME, Oliveira RB, Jorgetti V, Carvalho AB.
    J Bras Nefrol; 2010 Jun; 32(3):229-36. PubMed ID: 21103684
    [Abstract] [Full Text] [Related]

  • 4. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W, Chaiyakum A, Pongskul C.
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [Abstract] [Full Text] [Related]

  • 5. Bone health in chronic kidney disease-mineral and bone disease.
    Gal-Moscovici A, Sprague SM.
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):27-36. PubMed ID: 17200041
    [Abstract] [Full Text] [Related]

  • 6. Association of disorders in mineral metabolism with progression of chronic kidney disease.
    Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):825-31. PubMed ID: 17699293
    [Abstract] [Full Text] [Related]

  • 7. Review of dialysate calcium concentration in hemodialysis.
    Toussaint N, Cooney P, Kerr PG.
    Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
    [Abstract] [Full Text] [Related]

  • 8. All research does not a guideline make!
    Moorthi RN, Moe SM, Drüeke T, Uhlig K.
    Am J Kidney Dis; 2010 Apr; 55(4):631-4. PubMed ID: 20338464
    [No Abstract] [Full Text] [Related]

  • 9. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD, Alvarez-Ude F, Gil MT, Soriano A, Egea JJ, Millán I, Amoedo ML, Muray S, Carretón MA.
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [Abstract] [Full Text] [Related]

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 11. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism.
    González EA, Al-Aly Z, Martin KJ.
    Semin Dial; 2005 Nov; 18(3):171-4. PubMed ID: 15934956
    [Abstract] [Full Text] [Related]

  • 12. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.
    Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali C, London GM, Vanholder R.
    Nephrol Dial Transplant; 2010 Dec; 25(12):3823-31. PubMed ID: 20829401
    [Abstract] [Full Text] [Related]

  • 13. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F, Gorriz JL, Pallardo LM, Pons R, Santiago C, Multicentric group for the study of the phosphocalcic metabolism in the community of Valencia.
    J Nephrol; 2005 Dec; 18(6):739-48. PubMed ID: 16358233
    [Abstract] [Full Text] [Related]

  • 14. [Chronic kidney disease (CKD) and bone. Chronic kidney disease--mineral and bone disorder in predialysis patients].
    Inaguma D, Tatematsu M.
    Clin Calcium; 2009 Apr; 19(4):493-9. PubMed ID: 19329827
    [Abstract] [Full Text] [Related]

  • 15. [Pathogenesis and treatment of vascular calcification in CKD].
    Brancaccio D, Gallieni M, Pasho S, Fallabrino G, Olivi L, Volpi E, Ciceri P, Missaglia E, Ronga C, Brambilla C, Butti A, Rocca-Rey L, Chiarelli G, Cozzolino M.
    G Ital Nefrol; 2009 Apr; 26 Suppl 45():S20-7. PubMed ID: 19382090
    [Abstract] [Full Text] [Related]

  • 16. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [Abstract] [Full Text] [Related]

  • 17. [CKD-MBD (chronic kidney disease-mineral and bone disorder). CKD-MBD: chronic kidney disease-mineral and bone disorder].
    Mizobuchi M, Aoshima Y, Akizawa T.
    Clin Calcium; 2010 Jul; 20(7):995-1003. PubMed ID: 20585177
    [Abstract] [Full Text] [Related]

  • 18. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T, Yamamoto H.
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [Abstract] [Full Text] [Related]

  • 19. The case against calcium-based phosphate binders.
    Moe SM, Chertow GM.
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):697-703. PubMed ID: 17699275
    [Abstract] [Full Text] [Related]

  • 20. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
    Ishida M, Yao N, Yachiku S, Anzai T, Kobayashi T, Ishida H.
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.